3 Reasons to Buy Novavax, Inc.

Novavax's recent decline could be a compelling buying opportunity.

Mar 28, 2014 at 6:30PM

The health care sector has fallen hard over the past month, and small caps in particular have led the sector lower. Because of the indiscriminate nature of this drop, I believe this rapid downturn could be creating some buying opportunities for investors with a long-term outlook. For example, the recombinant nanoparticle vaccine maker Novavax (NASDAQ:NVAX) is now down over 30% this month, yet the company offers a couple of compelling reasons to be optimistic about its future. With this idea in mind, here are my top three reasons why Novavax could be a bargain at current levels.

Reason No. 1
Novavax offers investors a strong clinical pipeline with multiple vaccines that have blockbuster potential. Chief among these candidates is Novavax's experimental vaccine for respiratory syncytial virus. The World Health Organization estimates that there are around 64 million new cases of RSV each year, and there is no prophylactic vaccine available for the majority of patient types. Specifically, AstraZeneca's (NYSE:AZN) palivizumab (brand name Synagis) is available for preterm babies born earlier than 35 weeks, but there are no treatment options for infants or elderly patients who are highly susceptible to RSV infections. Novavax's mid-stage experimental RSV vaccine would target three distinct patient populations: infants, young children, and the elderly. Thus far, the company has successfully completed a mid-stage trial for women of child-bearing age, and plans on initiating further mid-stage trials for other target populations later this year.

Novavax also has a growing influenza vaccine clinical program indicated for both pandemic and seasonal influenza. It reported some notable successes at the mid-stage level for its influenza vaccines over the past two years, and more trials are planned to begin later this year. Although the exact pathway to licensure is uncertain, i.e., accelerated or normal, I believe it could have a commercially available influenza vaccine on the market by 2016.

In terms of the commercial opportunity for influenza, the global flu vaccine market is expected to rise to around $4 billion as early as next year. Moreover, three big pharmas dominate this market space, namely AstraZeneca, GlaxoSmithKline (NYSE:GSK), and Novartis AG (NYSE:NVS). What's key to understand is that both GlaxoSmithKline and Novartis have developed new flu vaccines within the past two years in order to meet the growing demand, yet there is still a chronic annual shortage, showing that there is room for another player in this market. 

Reason No. 2
One of the things I like most about Novavax is the fact that it has a stable revenue source via its contract with BARDA to develop the next generation of influenza vaccines. The initial three-year period of the award provided Novavax with $52 million in revenue that allowed the company to build and improve infrastructure without having to dilute shareholders. Last February, this award period was extended for an additional seven months. Not many developmental biotechs can offer investors stable revenue streams at this stage of their life cycle.

Reason No. 3
When considering speculative clinical-stage biotechs, one of the first things I look at is insider buying versus selling. In Novavax's case, the company's president, Stanley Erck, and vice president, "Buck" Phillips, have made a number of buys on the open market this year. Last week, this trend continued as they both purchased shares on the open market. As these top-level managers presumably know the most about their company, I view these insider buys as a positive.

Foolish wrap-up
Novavax shares more than doubled in the last year prior to this pullback. And despite this recent dip, they are still up 97% over the past 12 months, so they haven't exactly crashed. My view is that Novavax soared along with the rest of the sector and has simply fallen in conjunction with its peers. Going forward, however, I believe there will be fewer and fewer developmental biotechs that will outperform the broader market, and those that do will likely have success on the clinical front. Based on the clinical successes for Novavax's recombinant nanoparticle vaccine platform to date, this company looks like it could be one of those winners. You might want to dig deeper into this speculative biotech, especially after its relatively large pullback in the past month.

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


George Budwell has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers